Stocks · News reference
Arrowhead Pharmaceuticals has completed a refinancing of its $400 million credit facility with Sixth Street, reducing borrowing costs and extending debt maturity.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-04 AccNo: 0000879407-26-000063 Size: 258 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Arrowhead Pharmaceuticals, Inc. announced it will host a conference call and webcast on November 12, 2026, to discuss its financial results for the fiscal year ended September 30, 2026.
Arrowhead Pharmaceuticals announced it will present first-in-human trial data for its dual-functional RNAi molecule, ARO-DIMER-PA, at the American Heart Association Scientific Sessions 2026.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for REDEMPLO (plozasiran) to treat adults with Familial Chylomicronaemia Syndrome (FCS).
Arrowhead Pharmaceuticals announced that REDEMPLO (plozasiran) is now available on the NHS for adults in England and Wales with Familial Chylomicronaemia Syndrome (FCS).
Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.